Overexpression of SF3B1 and SF3B3 are associated with tamoxifen and fulvestrant resistance, and inhibition of another splicing factors, such as ZRANB2 and SYF2, reduces resistance to doxorubicin in breast cancer cells [20,21]. This evidence concerns the gene SF3B1 and breast cancer.